Accéder au contenu principal

GANDHI

- an ERA4Health research consortium

GANDHI

O-GlucNAcase in Acute Decompensated Heart Failure. From Bench to Bed-Side

Introduction & Scope

Rapid exacerbation of congestive heart failure, also known as acute decompensated heart failure (ADHF), represents a current major clinical challenge. Indeed, ADHF is the leading cause of hospitalization for people older than 65 years, representing 1 to 2 % of all hospitalization in Europe. Despite current treatments, ADHF is associated with high morbi-mortalitity and a poor quality of life for patients, as well causing a heavy burden for the  health-care systems and society. There is thus an urgent need of new concepts for tailored treatments to prevent or reduce ADHF. Recent studies have suggested that cardiac proteomic-metabolic remodelling may be a key driving force of aggravated cardiac dysfunction during the acute phase of ADHF.

We hypothesize that pharmacological treatments that restore protein modifications, i.e. inhibition of the enzyme O-GlcNAcase, may limit metabolic remodelling and ADHF.

The ultimate goal of GANDHI is to provide proof of concept for a new class of treatments for ADHF.

FACTS about ADHF

Acute decompensation of chronic Heart Failure (ADHF) is characterized by sudden and severe shortness of breath, edema, and fatigue. It is the most common cause of hospitalisation in people > 65 years of age. It can be caused by several factors including:

  • Atrial fibrillation
  • Infection
  • Acute hypertension
  • Emotional stress

Each decompensation episode renders patients prone for recurrent decompensation, and thus rehospitalization. Importantly, the are currently no medical treatments available to prevent recurrence of ADHF. To identify new treatments, we are focusing on investigating the mechanisms and treatment windows of a new class of pharmacological drugs targeting an enzyme (O-GlcNAcase) responsible for protein glycosylation*. The overall aim of the GANDHI project is to give solid proof of concept for the use of new treatments in ADHF, in order to improve the prognosis and quality of life of patients.

*glycosylation = addition of sugar moieties to proteins

MEET the SCIENTISTS